UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE NEW ORLEANS – A first-of-its-kind drug known as modakafusp alfa has shown early potential in combating multiple myeloma, a form of bone marrow cancer, in a study presented by researchers from the University of Pennsylvania’s Abramson Cancer Center at the 2022 American Society of Hematology (ASH) Annual Meeting (Abstract 565). Patients in...
Tag: <span>multiple myeloma</span>
Post
FDA OKs Teclistamab for Relapsed/Refractory Multiple Myeloma
M. Alexander Otto, PA, MMS October 25, 2022 The US Food and Drug Administration (FDA) has granted accelerated approval to teclistamab (Tecvayli, Janssen Biotech, Inc.) for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The results made the...
Post
CAR T-cell therapy proves effective in first trial in patients with resistant multiple myeloma
by Roswell Park Comprehensive Cancer Center Credit: CC0 Public Domain A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Roswell...
Post
Novel drug shows promising efficacy for patients with multiple myeloma
by Jenny Owen, Emory University Scanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAID Results of an international clinical trial co-led by researchers at Winship Cancer Institute at Emory University show potential for a novel drug to benefit patients with multiple...
Post
Improved survival in multiple myeloma patients following three-drug therapy with autologous stem cell transplant
by Dana-Farber Cancer Institute Credit: Pixabay/CC0 Public Domain Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option....
Post
Standard test for multiple myeloma provides clues of a rare, more deadly type
by Medical College of Georgia at Augusta University Dr. Gurmukh Singh. Credit: Michael Holahan, Augusta University A test for the common blood cancer multiple myeloma also holds clear clues that the patient has one of the most uncommon and deadly forms of this cancer, investigators say. While there is a specific test for this rare...
Post
FDA approves cilta-cel for multiple myeloma
A laboratory technician carries a cryogenic container of blood to be treated before genetically modifying a patient’s immune cells in the laboratory. March 8, 2019, at a production laboratory unit of the Paoli-Calmettes Institute in France. GERARD JULIEN/AFP via Getty Images On February 28, 2022, the Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (cilta-cel)...
Post
A myeloma-targeting monoclonal antibody offers new hope for treating multiple myeloma
by Osaka University Summary of the research. Credit: Naoki Hosen Multiple myeloma (MM) is a largely incurable cancer of plasma cells with an extremely poor prognosis. However, investigators from Japan have recently found that a common component of amino acid transporters, CD98 heavy chain, represents an effective monoclonal antibody target in treating MM. In a...
Post
Identification of a novel therapeutic target in Multiple Myeloma
INSTITUT PASTEUR Multiple myeloma is a cancer of the bone marrow, with a life expectancy of less than 5 years post-diagnosis. Proteasome inhibitors, the therapeutic backbone of current treatments, are very effective in treating newly diagnosed cancers but resistance or intolerance to these molecules inevitably develop, leading to relapses. While studying a neglected tropical disease,...
Post
Oncotarget: TAK1-inhibitors are cytotoxic for multiple myeloma cells
IMPACT JOURNALS LLC IMAGE: NG25 REDUCE VIABILITY OF CD138+ CELLS FROM PATIENTS, ALONE AND IN COMBINATION WITH MELPHALAN. (A) CD138+ CELLS FROM 10 INDIVIDUAL DONORS WERE TREATED WITH NG25 BEFORE CELL VIABILITY WAS MEASURED. INDIVIDUAL DONORS, MEAN, AND SD ARE SHOWN. ASTERISKS INDICATE STATISTICALLY SIGNIFICANT DIFFERENCES (KRUSKAL-WALLIS TEST, DUNN’S MULTIPLE COMPARISON TEST, P < 0,05)....
- 1
- 2